Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) with companion diagnostics. Its programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. The companys lead FAK inhibitor, VS-6063, is in Phase I/Ib testing in ovarian cancer, as well as developing for the treatment of mesothelioma and breast cancer. It is also developing FAK inhibitor VS-4718 and PI3K/mTOR inhibitor VS-5584 in patients with advanced cancers. The companys product candidates target CSCs that have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance. Verastem, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
February 9, 2021
RegMed Investors’ (RMi) closing bell: markets fluctuate as sector poops the bed, sixth session streak is over
February 9, 2021
RegMed Investors’ (RMi) pre-open: a correction could be catching-up to us
February 2, 2021
RegMed Investors’ (RMi) closing bell: sector’s staying in the upside
January 29, 2021
RegMed Investors’ (RMi) closing bell: sector’s low volume doesn’t reflect volatility as share pricing gets overpowered
January 28, 2021
RegMed Investors’ (RMi) pre-open: why the “bail”, the tail risks have gotten just too skewed
January 27, 2021
RegMed Investors’ (RMi) closing bell: wipe-out as negativity festers the sector and markets
January 25, 2021
RegMed Investors’ (RMi) closing bell: a ying-yang sector, who’s performing and which are not
January 22, 2021
RegMed Investors’ (RMi) closing bell: bounce-back BUYs were up today
January 21, 2021
RegMed Investors’ (RMi) closing bell: slim pickings in the upside
35 companies, 1 interpreter!
Insight, foresight and recommendation
Verastem (VSTM) -- Opened 2018 at $3.21, started February at $3.55 and March at $3.05 with a high of $3.24 on 3/6 - neeeds news which always stimulates volume and pricing offsetting complacency in share pricing ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.